Independent predictors of the primary endpoint of death, non-fatal myocardial infarction, prolonged ventricular arrhythmia or hospitalisation with unstable angina or heart failure
| HR (95% CI)* | p Value | |
| Final model with new hyperenhancement as a categorical variable: | ||
| Presence of new hyperenhancement (y/n) | 3.11 (1.43 to 6.77) | 0.004 |
| Addition of extra variables:† | ||
| LVEF after revascularisation (%) | 0.98 (0.95 to 1.02) | 0.31 |
| Troponin after revascularisation (μg/l) | 1.02 (0.96 to 1.08) | 0.52 |
| Troponin after revascularisation >0.2 μg/l‡ | 1.26 (0.33 to 4.73) | 0.73 |
| PMI | 1.36 (0.46 to 4.03) | 0.57 |
| All other variables from table 2 | >0.10 | |
| Final model with new hyperenhancement as a continuous variable: | ||
| New hyperenhancement (g) | 1.10 (1.03 to 1.17) | 0.005 |
| Addition of extra variables:¶ | ||
| LVEF after revascularisation (%) | 0.99 (0.95 to 1.02) | 0.49 |
| Troponin after revascularisation (μg/l) | 1.01 (0.96 to 1.07) | 0.71 |
| Troponin after revascularisation >0.2 μg/l | 1.25 (0.43 to 3.61) | 0.68 |
| PMI | 1.58 (0.58 to 4.41) | 0.88 |
| All other variables from table 2 | >0.10 |
-
*All models were adjusted for age and sex.
-
†After inclusion of each of the extra variables, HR for new hyperenhancement remained >2.6 with p value <0.05.
-
‡0.2 μg/l equals the 99th centile of the lower limit of quantification.
-
¶After inclusion of each of the extra variables, HR for new hyperenhancement (continuous) remained >1.08 with p value <0.05.
-
LVEF, denotes left ventricular ejection fraction; PMI, procedure-related myocardial infarction according to the ESC/ACC/AHA/WHF guidelines.
